Are children with lesser-risk B-lineage acute lymphoblastic leukemia curable with antimetabolite therapy?

被引：0
作者：
Ching-Hon Pui
William E Evans
Mary V Relling
机构：
[1] St Jude Children's Research Hospital,C
[2] Memphis,H Pui is Chair of the Department of Oncology, WE Evans is the Director and Chief Executive Officer and MV Relling is Chair of the Department of Pharmaceutical Science
[3] TN,undefined
[4] USA.,undefined
来源：
Nature Clinical Practice Oncology | 2008年 / 5卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：130 / 131
页数：1
相关论文
共 6 条
  • [1] Pui CH(2006)Treatment of acute lymphoblastic leukemia N Engl J Med 354 166-178
  • [2] Evans WE(2007)Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201 Blood 110 1105-1111
  • [3] Chauvenet AR(2004)Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital Blood 104 2690-2696
  • [4] Pui CH(1999)Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells: relation to thiopurine metabolism Cancer 86 1080-1086
  • [5] Bo J(2006)Thiopurine methyltransferase in acute lymphoblastic leukemia Blood 107 843-844
  • [6] Relling MV(undefined)undefined undefined undefined undefined-undefined
1